YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (1558.HK)
HKD 12.48
(-1.42%)
HKD 12.48
(-1.42%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 2.74 Billion CNY | 376.64% |
| 2022 | 691.48 Million CNY | 434.77% |
| 2021 | -206.55 Million CNY | -121.74% |
| 2020 | 950.23 Million CNY | -63.61% |
| 2019 | 2.61 Billion CNY | 128.16% |
| 2018 | 1.14 Billion CNY | 41.95% |
| 2017 | 806.27 Million CNY | 80.37% |
| 2016 | 447.01 Million CNY | 25.86% |
| 2015 | 355.16 Million CNY | 64.36% |
| 2014 | 216.09 Million CNY | 71.07% |
| 2013 | 126.32 Million CNY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 9 Billion CNY | 500.69% |
| 2023 Q2 | 1.67 Billion CNY | 509.93% |
| 2023 FY | - CNY | 376.64% |
| 2023 Q4 | 1.49 Billion CNY | -10.38% |
| 2022 Q4 | 274.3 Million CNY | -34.25% |
| 2022 FY | - CNY | 434.77% |
| 2022 Q2 | 417.18 Million CNY | 140.63% |
| 2021 FY | - CNY | -121.74% |
| 2021 Q2 | -379.92 Million CNY | -4327.53% |
| 2021 Q4 | 173.37 Million CNY | 145.63% |
| 2020 Q2 | 958.81 Million CNY | -24.39% |
| 2020 FY | - CNY | -63.61% |
| 2020 Q4 | -8.58 Million CNY | -100.89% |
| 2019 FY | - CNY | 128.16% |
| 2019 Q4 | 1.26 Billion CNY | -5.58% |
| 2019 Q2 | 1.34 Billion CNY | 258.57% |
| 2018 FY | - CNY | 41.95% |
| 2018 Q4 | 374.59 Million CNY | -51.35% |
| 2018 Q2 | 769.93 Million CNY | 79.49% |
| 2017 Q2 | 377.32 Million CNY | 128.34% |
| 2017 FY | - CNY | 80.37% |
| 2017 Q4 | 428.95 Million CNY | 13.68% |
| 2016 Q2 | 281.77 Million CNY | 94.72% |
| 2016 FY | - CNY | 25.86% |
| 2016 Q4 | 165.24 Million CNY | -41.35% |
| 2015 Q2 | 210.45 Million CNY | 141.56% |
| 2015 Q4 | 144.7 Million CNY | -31.24% |
| 2015 FY | - CNY | 64.36% |
| 2014 Q2 | 128.96 Million CNY | 117.31% |
| 2014 Q4 | 87.12 Million CNY | -32.45% |
| 2014 FY | - CNY | 71.07% |
| 2013 FY | - CNY | 0.0% |
| 2013 Q4 | 59.34 Million CNY | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 150.4 Million HKD | -1725.428% |
| Grand Pharmaceutical Group Limited | 2.96 Billion HKD | 7.454% |
| Extrawell Pharmaceutical Holdings Limited | -129.51 Million HKD | 2219.706% |
| Wai Yuen Tong Medicine Holdings Limited | 113.79 Million HKD | -2312.558% |
| Qianhai Health Holdings Limited | -50.22 Million HKD | 5565.852% |
| Lee's Pharmaceutical Holdings Limited | 109.82 Million HKD | -2399.948% |
| Essex Bio-Technology Limited | 418.37 Million HKD | -556.213% |
| Tongfang Kontafarma Holdings Limited | 76.63 Million HKD | -3482.586% |
| PuraPharm Corporation Limited | -26.16 Million HKD | 10591.203% |
| SSY Group Limited | 2.11 Billion HKD | -29.835% |
| JBM (Healthcare) Limited | 204.39 Million HKD | -1243.237% |
| Jacobson Pharma Corporation Limited | 429.92 Million HKD | -538.592% |
| China Resources Pharmaceutical Group Limited | 15.43 Billion HKD | 82.208% |